Nebenwirkungen · Olanzapine Glenmark
Olanzapine Glenmark 5 mg tablets · Abschnitt 4.8 · PDF-Seite 27
HOS-211021 · Präparat HOS-154617
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term clinical trials in adolescent patients. Clinically significant weight gain (≥ 7 %) appears to occur more frequently in the adolescent population compared to adults with comparable exposures. The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T12:02:00Z · SHA-256 40d8b80ed75e6ad735ceb7de61ff249ac2241e6137cc6150ff392f2c4056dab6 · Passage a67d5f9a04c8350bdcdee6d5dff773b6c74ceb0bf2b054ce943b8efce36241ec · Zeichen 12653–13252 im Abschnitt